174 related articles for article (PubMed ID: 36877894)
1. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Yao Y; Ng JF; Park WD; Samur M; Morelli E; Encinas Mayoral J; Chyra Z; Xu Y; Derebail S; Epstein C; Nabet B; Chesi M; Gray NS; Young RA; Kwiatkowski N; Mitsiades C; Anderson KC; Lin CY; Munshi NC; Fulciniti M
Blood; 2023 Jun; 141(23):2841-2852. PubMed ID: 36877894
[TBL] [Abstract][Full Text] [Related]
2. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract][Full Text] [Related]
3. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
4. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Olson CM; Liang Y; Leggett A; Park WD; Li L; Mills CE; Elsarrag SZ; Ficarro SB; Zhang T; Düster R; Geyer M; Sim T; Marto JA; Sorger PK; Westover KD; Lin CY; Kwiatkowski N; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):792-803.e10. PubMed ID: 30905681
[TBL] [Abstract][Full Text] [Related]
5. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
6. An integrative multi-omics approach uncovers the regulatory role of CDK7 and CDK4 in autophagy activation induced by silica nanoparticles.
Ruan C; Wang C; Gong X; Zhang Y; Deng W; Zhou J; Huang D; Wang Z; Zhang Q; Guo A; Lu J; Gao J; Peng D; Xue Y
Autophagy; 2021 Jun; 17(6):1426-1447. PubMed ID: 32397800
[TBL] [Abstract][Full Text] [Related]
7. Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Ohguchi H; Park PMC; Wang T; Gryder BE; Ogiya D; Kurata K; Zhang X; Li D; Pei C; Masuda T; Johansson C; Wimalasena VK; Kim Y; Hino S; Usuki S; Kawano Y; Samur MK; Tai YT; Munshi NC; Matsuoka M; Ohtsuki S; Nakao M; Minami T; Lauberth S; Khan J; Oppermann U; Durbin AD; Anderson KC; Hideshima T; Qi J
Blood Cancer Discov; 2021 Jul; 2(4):370-387. PubMed ID: 34258103
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
9. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
10. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
[TBL] [Abstract][Full Text] [Related]
11. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
[TBL] [Abstract][Full Text] [Related]
13. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract][Full Text] [Related]
14. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
[TBL] [Abstract][Full Text] [Related]
15. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
16. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Zhang H; Christensen CL; Dries R; Oser MG; Deng J; Diskin B; Li F; Pan Y; Zhang X; Yin Y; Papadopoulos E; Pyon V; Thakurdin C; Kwiatkowski N; Jani K; Rabin AR; Castro DM; Chen T; Silver H; Huang Q; Bulatovic M; Dowling CM; Sundberg B; Leggett A; Ranieri M; Han H; Li S; Yang A; Labbe KE; Almonte C; Sviderskiy VO; Quinn M; Donaghue J; Wang ES; Zhang T; He Z; Velcheti V; Hammerman PS; Freeman GJ; Bonneau R; Kaelin WG; Sutherland KD; Kersbergen A; Aguirre AJ; Yuan GC; Rothenberg E; Miller G; Gray NS; Wong KK
Cancer Cell; 2020 Jan; 37(1):37-54.e9. PubMed ID: 31883968
[TBL] [Abstract][Full Text] [Related]
17. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
18. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription.
Rimel JK; Poss ZC; Erickson B; Maas ZL; Ebmeier CC; Johnson JL; Decker TM; Yaron TM; Bradley MJ; Hamman KB; Hu S; Malojcic G; Marineau JJ; White PW; Brault M; Tao L; DeRoy P; Clavette C; Nayak S; Damon LJ; Kaltheuner IH; Bunch H; Cantley LC; Geyer M; Iwasa J; Dowell RD; Bentley DL; Old WM; Taatjes DJ
Genes Dev; 2020 Nov; 34(21-22):1452-1473. PubMed ID: 33060135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
